Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

BMC Urology

Table 1 Characteristics of patients and the results of the log-rank test of prognostic factors

		Median (range)	No. of patients	No. of CRPC	Median progression time (months)		No. of deaths	Median survival time (months)
Total			286	207	19		102	113
Age		73 (50–91)
	≤75		179	132	19		69	85
	≥76		107	75	18	n.s.	33	none	n.s.
T	T1		4	2	57	*(T2 vs. T3, T4)	0	all alive
	T2		31	18	37		9	111
	T3		162	114	19		60	83
	T4		89	73	14		33	77	n.s.
N	N0		164	116	19		59	79
	N1		122	91	19	n.s.	43	99	n.s.
M	M0		50	31	26		9	99
	M1		236	176	18	n.s.	93	83	n.s.
Gleason score	6-8		181	83	21	*	63	115
	9-10		105	124	14	*	39	85	n.s.
PSA at diagnosis		174 (5.7-21864)
	<100		105	64	23	*(<100 vs. ≥500)	31	85
	100-500		97	73	16		36	113
	≥500		84	70	15		35	none	n.s.
Nadir PSA level		0.3 (0.001-650)
	<0.2		122	71	38	**	26	115	***
	0.2-4		112	86	13		44	62
	≥4		52	50	8		32	25
Time from PADT to Nadir		9.45 (1–64)
	≥12		114	74	35	**	23	113	***
	6-12		83	62	13		39	79
	<6		89	71	7		40	28
Time from PADT to CRPC		13 (1–97)
	No CRPC		79				14	none
	≥12		112				32	113	***
	6-12		63				34	35
	<6		32				22	21

ISSN: 1471-2490